There was only problem, it didn't work. The wonder drug, gavestinel, failed to 
produce any significant treatment benefits for patients treated within six hours 
after experiencing an acute ischemic stroke, according to the recent results of 
a major clinical trial of the neuroprotectant. The outcome has dimmed the 
optimism of hospitalists that rapid treatment would dramatically improve patient 
outcomes.